This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 2001.
Company Filing History:
Years Active: 2001
Title: Maynard D Carty: Innovator in Transgenic Animal Models for Diabetes Research
Introduction
Maynard D Carty is a notable inventor based in Gales Ferry, Connecticut. He has made significant contributions to the field of biomedical research, particularly in the development of transgenic animal models for studying Type II diabetes mellitus. His innovative work has the potential to advance the understanding and treatment of this prevalent disease.
Latest Patents
Carty holds a patent for "Transgenic animal models for type II diabetes mellitus." This patent describes the generation of transgenic animal models that are essential for testing various treatments for Type II diabetes. The DNA construct developed by Carty allows for pancreatic β cell-specific expression of human islet associated polypeptide (IAPP) under the regulation of the rat insulin II promoter. This construct can be introduced into animal embryos through microinjection or into established cell lines via electroporation. The resulting transgenic animals exhibit symptoms such as amyloid plaque deposits in the islets of Langerhans, fasting hyperglycemia, glycosuria, and diabetic glomerulosclerosis by the age of 3 to 5 months. These models are invaluable for screening treatments that can either enhance or inhibit the progression of diabetes.
Career Highlights
Carty is currently associated with Pfizer Corporation, where he continues to contribute to innovative research in the field of diabetes. His work at Pfizer has allowed him to collaborate with leading scientists and researchers, further enhancing the impact of his inventions.
Collaborations
Throughout his career, Carty has worked alongside esteemed colleagues such as Walter C Soeller and David K Kreutter. These collaborations have fostered a rich environment for innovation and have led to significant advancements in diabetes research.
Conclusion
Maynard D Carty's contributions to the field of diabetes research through his innovative transgenic animal models are noteworthy. His work not only enhances our understanding of Type II diabetes but also paves the way for potential treatments. Carty's dedication to research exemplifies the spirit of innovation in the biomedical field.